About Us

180 Life Sciences is developing new treatments for one of the world's biggest drivers of disease: inflammation.

The company consists of three programs developing novel drugs for treating distinct inflammatory diseases. These programs are led by world-leading scientists at prestigious universities who have already developed blockbuster drugs and made ground-breaking discoveries in their fields. One of the programs is conducting a phase 2b/3 trial and expects its first results in Q4 2021. Other clinical trials are expected to begin by the end of 2021.

Professor Sir Marc Feldmann with his Lasker Award, European Inventor of the Year Award, and Gairdner Award

Professor Raphael Mechoulam receiving an honorary doctorate in Madrid

Professor Lawrence Steinman and Dr Jonathan Rothbard in Stanford University

180 Life Sciences Development Programs

TECHNOLOGIESRepurposing of anti-TNF for major unmet needs, other patented drugsNovel non-psychoactive synthetic CBD analogsNovel α7nAChR agonists
• Early stage Dupuytren’s disease (DD)
• Frozen Shoulder
• Post Operative Delirium/Cognitive Deficit (POCD)
• Non-Alcoholic Steatohepatitis (NASH)
• Arthritis
• Pain/Inflammation
• Smoking cessation induced Ulcerative Colitis (UC) initially
• Other inflammatory indications will be targeted after results in UC
COMPETITIVE ADVANTAGE• DD: no treatment for early disease
• Frozen Shoulder: local steroid only for short term pain relief, does not modulate long-term disease activity
• POCD: No treatment available
• Novel, >99.5% pure,
• Robust batch to batch consistency (non-botanical)
• Developing advanced formulation for increased bioavailability
• Orally available
• Potentially as effective as biologics (like anti-TNF)
• Proven lack of toxicity
STAGE• DD: Phase 2b/3 in early DD, results Q4 2021*
• Frozen Shoulder: Initiate Phase 2 trials Q3 2021
• POCD: Initiate Phase 2 trials Q4 2021
• NASH: Preclinical studies started Q2 2020
• Preclinical – lead SCAs and formulations being identified
• Trials planned in arthritis and pain
• Preclinical – optimizing new compounds based on safe a7nAchR agonists
INTELLECTUAL PROPERTY• Patents issued for treatment of DD & POCD with anti-TNF
• Additional patents issued (anti-IL-33) or pending in localized and systemic fibrosis and delivery systems
• Patent issued for Cyclohexenyl compounds, compositions and uses thereof
• Patents pending & to be filed
• Three patents issued, one patent pending

*Regulatory approvals obtained from the MHRA and CCMO and the relevant accredited ethics committees to perform clinical trials in the UK and The Netherlands. No meetings have been held with, and no applications or requests for approval have been submitted to the FDA for any products at this time.


180 Life Sciences hold a variety of patents across all our programs.
To view current patent information, please download the pdf​

180 Life Sciences

US Headquarters
3000 El Camino Real
Bldg. 4, suite 200,
Palo Alto, CA 94306

tel. (650) 507-0669

UK Headquarters
116 Baker St
London W1U 6TS

Get in touch with our team

Raphael Mechoulam


Father of cannabis research, having worked on the chemistry, pharmacology and clinical effects of natural products, including cannabis for over 50 years. He isolated numerous cannabinoids, including the active constituent of cannabis, delta9-THC, and elucidated its structure. This also paved the way to his discovery of 2AG and anandamide, both endogenous cannabinoids in late 1990s. He has published over 400 papers in esteemed scientific journals and be awarded several notable prizes including the Israeli Prize in Exact Sciences in 2000, NIDA discovery award in 2011, 2012 Rothschild Prize in Chemical Sciences and Physical Sciences, and Lifetime achievement award at CannaMed in 2016. Currently his work focusses on generating novel cannabinoids and anandamide-like compounds which are being developed as drugs.

Fibrosis of the Liver (NASH)

  • Most commonly caused by non-alcoholic fatty liver disease (NAFLD), which affects ~30% of the US population
  • ~2% of patients with non-alcoholic fatty liver disease and 15-20% with non-alcoholic steatohepatitis (NASH) progress to cirrhosis
  • No approved therapeutic for NASH
  • Lab program in collaboration with Celgene-BMS for target discovery using human liver samples

Frozen Shoulder

  • Affects 9% of the of the population aged 25-64yr, more common in diabetics
  • Only treatment for early stage is local steroid injection for short term relief
  • Phase 2 clinical trials planned for local injection of anti-TNF, initiates Q3 2021 in the UK
  • Trial protocol completed and £250,000 NIHR grant received

Post Operative Delirium/Cognitive Deficit (POCD)

  • Over 300,000 hip fractures each year in the U.S. alone
  • Strong clinical evidence for anti-TNF as preventative therapy
  • Patent claims granted, patent is licensed from Kennedy Trust, UK
  • Phase 2 multi-centre trial of pre-operative anti-TNF in hip fracture surgery planned to initiate by Q4 2021, single dose administered just prior to surgery, to be complete in 4 years

Ozan Pamir

Chief Financial Officer

Ozan has played a key role in the formation of 180 Life Sciences as the CFO of two of the subsidiaries since late 2018 and oversaw the merger of 180 Therapeutics, Katexco and Cannbiorex, which now form 180 Life Sciences. He was instrumental in completing the company’s NASDAQ listing and managed majority of the funding rounds for the company.

Throughout his career, Ozan has specialized in helping companies in defining their corporate strategy, and executing corporate transactions such as M&As and IPOs. He brings a wealth of knowledge and experience to the 180 Life Sciences team as a former investment banker with in-depth capital markets expertise. Ozan was previously VP of Investment Banking at a leading Canadian independent investment bank, where he co-founded the origination department which focused on small and mid-cap financing and advisory mandates. In this role he advised private and public companies on M&A deals and was the lead banker on more than 30 financings, raising approximately $400 million.

After his investment banking career, Ozan became a venture capitalist with a hands on approach, where he gained valuable experience as CFO and/or board member to early stage biotech companies. Ozan was the CFO of Enosi Life Sciences and the CFO and a board member of Unify Pharmaceuticals, both pre-clinical companies focused on autoimmune diseases.

Ozan holds an Economics and Finance degree from McGill University and is a CFA Charterholder.

Fiona McCann

Scientific Director

Fiona McCann PhD is an immunologist and has held the role of Scientific Director at 180 Life Sciences in UK since September 2018. 

Fiona has obtained her PhD from studies at Pfizer and University of Kent, UK in 2000. 

Since then she has carried out translational research at Imperial College London, and Kennedy Institute of Rheumatology (KIR), and has published several high impact studies with pharmaceutical companies (including Bayer Schering, Celgene, GSK) which unravel novel mechanisms of immune regulation, harnessing potential for therapeutic discovery. 

From 2011-2018, she was group leader for therapeutic target discovery in autoimmune disease and fibrosis at University of Oxford, firstly working with NovoNordisk, and secondly with a multi-national consortium of academics and pharma at KIR/SGC Oxford (EU/IMI funded). 

She holds a mini-MBA from SAID Business School, University of Oxford, a certificate in Entrepreneurs in Clinical Academia (ECA/FOCIS) from INSEAD business school, Fontainebleau, France and is currently studying towards a certificate in Project Management in Biotech at University of Washington and UCSD, due to complete June 2021. 


Prof Jagdeep Nanchahal

Chairman of Clinical Advisory Board

Professor Nanchahal is a surgeon scientist at the University of Oxford, focused on defining the molecular mechanisms of common diseases such as fibrosis and translating his findings through to early phase clinical trials

His surgical background has allowed him to bring a unique insight to common, yet relatively neglected diseases

Many of his findings stem from investigations in primary human tissues, rather than relying on animal models that often fail to recreate human clinical conditions

He has pioneered the treatment of fibrosis of the hand (Dupuytren’s disease), which unlike fibrosis in major human tissues can be diagnosed early and samples easily obtained to discover new pathways of importance

In 2013 his group identified TNF⍺ as a target for Dupuytren’s disease, leading to a phase 2a clinical trial to determine the effective dose and preparation of anti-TNF

He is now leading the Phase 2b/3 trial funded by the Wellcome Trust and UK Department of Health

Professor Nanchahal is a member of the Royal College of Plastic Surgeons

Dr Jonathan Rothbard

Chief Scientific Officer

Dr Jonathan Rothbard works in the neurology department at Stanford University

Dr Rothbard headed the Molecular Immunology Laboratory at the Imperial Cancer Research Fund in London in 1990, where he first worked with Professor Sir Marc Feldmann

He has collaborated with Professor Lawrence Steinman since 1986, when they published the first of their 26 manuscripts together

Dr Rothbard has been involved at a high level with start-up pharmaceuticals discovery; in 1987 he founded Amylin in San Diego and has also founded start-ups CellGate and ImmuLogic

Amylin was focused on the discovery, development and commercialization of drugs treating diseases including diabetes and obesity

The company was sold in 2012 to Bristol-Myers Squibb for $5.4 billion

In addition to neurology, Dr Rothbard has also worked in the departments of chemistry and rheumatology at Stanford University

Dr Rothbard holds a BA from Hamilton College and a PhD from Columbia University, which he followed with a fellowship at The Rockefeller University

Prof Lawrence Steinman


Professor Lawrence Steinman is currently is the George A. Zimmermann Endowed Chair in the Neurology Department at Stanford University

His specialities lie in autoimmune diseases, particularly multiple sclerosis and neuromyelitis optica

In the Steinman Laboratory of Stanford, which is his foundation, he has developed new therapies for autoimmune diseases, some of which are in advanced clinical trials

Professor Steinman has overseen success in the pharmaceuticals industry; he was on the board of Centocor, sold to Johnson and Johnson in 1998 for $4.9 billion, and was a founder of Neurocrine Biosciences (NASDAQ:NBIX) which went public in 1997

Professor Steinman was instrumental in discovering the application of natalizumab (Tysabri) in treating multiple sclerosis. The drug was sold to Royalty Pharma in 2017 for $2.85 billion

Recognition for his work includes the Friedrich Sasse Award in 1994, the John Dystel Prize in 2004, the Charcot Prize for Lifetime Achievement in Multiple Sclerosis Research in 2011, and the Anthony Cerami Award in Translational Medicine in 2015

He has twice been awarded the Senator Jacob Javits Award by the US Congress, in 1988 and 2002

Professor Steinman is a member of both the National Academy of Medicine and the National Academy of Sciences

Prof Sir Marc Feldmann


Professor Sir Marc Feldmann, AC FAA FRS FRCP FRCPath FMedSci is a pre-eminent immunologist, and an Emeritus professor at the University of Oxford.

At the Kennedy Institute in London in the 1980s, he identified TNF as a target in the treatment of arthritis. With his research partner, Prof Sir Ravinder Maini, they led clinical trials of monoclonal antiTNF antibody in treatment resistant rheumatoid arthritis, which Centocor had generated, and now called Infliximab, which J&J now sells as Remicade.

This work was highly recognized, leading to many prestigious awards including the Crafoord prize of the Royal Swedish Academy, the Albert Lasker award for clinical medical research, the Canada Gairdner award, the Paul Janssen award and the European Inventor of the year award, and most recently (2020) the Tang Prize.

Remicade was the main driver of the $4.9 billion USD acquisition of Centocor by Johnson and Johnson in 1998. Since its approval Remicade has sold over $50 billion USD worldwide, and remains J&J’s biggest selling drug. Feldmann and Maini are credited for the generation of anti-TNFs as the world’s biggest drug class since 2013, with global sales of $36 to 40 Bn in recent years. This major impact on medical therapy led to his receiving a knighthood and also the Australian equivalent, Companion of the Order of Australia ( AC ).

Sir Marc Feldmann is a fellow of the Royal Society, Australian Academy of Science and a Foreign Member of the National Academy of Sciences, USA.

Dr Jim Woody

Chief Executive Officer

Jim Woody has more than 25 years of pharmaceutical research and management expertise

He currently serves as Chairman of Oncomed Pharmaceuticals, where he was previously a founder and CEO; he is also a General Partner at Latterell Venture Partners, a venture capital group focusing on early-stage healthcare companies

He has served in a variety of health and management roles including as President of Roche Bioscience, and CSO and Senior Vice President of R&D for Centocor.

At Centocor, Jim was part of the team that discovered Remicade, used to treat arthritis and which is now one of the best-selling drugs in the world.

He served as Commanding Officer and Director at the US Naval Medical Research and Development Command in Bethesda, Maryland

In this role he was responsible for the surveillance, detection and therapy for all biologic warfare agents and infectious diseases in the First Gulf War; he was awarded the US Navy Legion of Merit for his service

He holds an MD from Loma Linda University, and trained in pediatric immunology at Duke University and Boston Children’s Hospital (Harvard)

He further holds a PhD in Immunology from the University of London, and has co-authored more than 140 publications